<em>In vivo</em> isolation of circulating tumor cells in patients with different stages of prostate cancer

Theil,Gerit; Boehm,Catrin; Fischer,Kersten; Bialek,Joanna; Hoda,Raschid; Weber,Ekkehard; Schönburg,Sandra; Kawan,Felix; Fornara,Paolo

doi:10.3892/ol.2021.12618

In vivo isolation of circulating tumor cells in patients with different stages of prostate cancer

Authors:
- Gerit Theil
- Catrin Boehm
- Kersten Fischer
- Joanna Bialek
- Raschid Hoda
- Ekkehard Weber
- Sandra Schönburg
- Felix Kawan
- Paolo Fornara
View Affiliations

Affiliations: Medical Faculty of Martin Luther University Halle‑Wittenberg, University Clinic and Outpatient Clinic for Urology, D-06120 Halle (Saale), Germany, Institute of Physiological Chemistry, Medical Faculty of Martin Luther University Halle‑Wittenberg, D‑06120 Halle (Saale), Germany
Published online on: March 4, 2021 https://doi.org/10.3892/ol.2021.12618
Article Number: 357
Copyright: © Theil et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Circulating tumor cells (CTCs) provide accurate information on the clinical stage of cancer progression. The present study examined the clinical validity and feasibility of a new medical device for the in vivo isolation of CTCs from the blood of patients with prostate cancer (PCa). The GILUPI CellCollector^® (DC01) was applied in 188 cases. The CTC/prostate‑specific antigen (PSA) profile of each patient was checked for therapeutic monitoring of patients with PCa. The CellCollector, which is a unique in vivo approach for the isolation of CTCs, was compared with the CellSearch^® system, which is the current standard. Overall survival (OS) and diagnostic performance were evaluated. By in vivo isolation, 78.9% (56/71) of patients with metastatic disease (PCa‑m) and 46.3% (24/53) of patients with localized disease (PCa‑l) had ≥1 captured CTC. Kaplan‑Meier analysis revealed that patients with PCa‑m that had ≥5 CTCs had a significantly different OS compared with those with <5 CTCs (27.5 months vs. 37 months; HR 2.6; 95% CI 0.78‑8.3). Patients with a higher number of CTCs at all time‑points had the shortest median OS of 25 months (HR 1.9; 95% CI 0.4‑11.6). The effectiveness of CTC isolation technologies demonstrated that in 65.7% of the applications, patients with cancer were positive for CTCs using the CellCollector. By contrast, the CellSearch system detected CTCs in 44.4% of applications. In vivo isolation of CTCs demonstrated the clinical viability of the CellCollector, related to the current standard for the isolation of CTCs from patients with PCa. The advantage of the in vivo device is that it overcomes the blood volume limitations of other CTC assays. Furthermore, the present study revealed that the CellCollector was well tolerated, and no adverse events (AEs) or serious AEs were reported.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S and Antonarakis ES: Update on systemic prostate cancer therapies: Management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 75:88–99. 2019. View Article : Google Scholar : PubMed/NCBI
3	Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, et al: Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 368:436–445. 2013. View Article : Google Scholar : PubMed/NCBI
4	Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, et al: Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2:1441–1449. 2016. View Article : Google Scholar : PubMed/NCBI
5	Hofman P and Popper HH: Pathologists and liquid biopsies: To be or not to be? Virchows Arch. 469:601–609. 2016. View Article : Google Scholar : PubMed/NCBI
6	Alix-Panabieres C and Pantel K: Challenges in circulating tumour cell research. Nat Rev Cancer. 14:623–631. 2014. View Article : Google Scholar : PubMed/NCBI
7	Yap TA, Lorente D, Omlin A, Olmos D and de Bono JS: Circulating tumor cells: A multifunctional biomarker. Clin Cancer Res. 20:2553–2568. 2014. View Article : Google Scholar : PubMed/NCBI
8	Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et al: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 371:1028–1038. 2014. View Article : Google Scholar : PubMed/NCBI
9	Andree KC, van Dalum G and Terstappen LW: Challenges in circulating tumor cell detection by the CellSearch system. Mol Oncol. 10:395–407. 2016. View Article : Google Scholar : PubMed/NCBI
10	Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW and Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
11	de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ and Raghavan D: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 14:6302–6309. 2008. View Article : Google Scholar : PubMed/NCBI
12	Habli Z, AlChamaa W, Saab R, Kadara H and Khraiche ML: Circulating tumor cell detection technologies and clinical utility: Challenges and opportunities. Cancers (Basel). 12:19302020. View Article : Google Scholar
13	Ferreira MM, Ramani VC and Jeffrey SS: Circulating tumor cell technologies. Mol Oncol. 10:374–394. 2016. View Article : Google Scholar : PubMed/NCBI
14	Theil G, Fischer K, Weber E, Medek R, Hoda R, Lucke K and Fornara P: The use of a new CellCollector to isolate circulating tumor cells from the blood of patients with different stages of prostate cancer and clinical outcomes-a proof-of-concept study. PLoS One. 11:e01583542016. View Article : Google Scholar : PubMed/NCBI
15	Gorges TM, Penkalla N, Schalk T, Joosse SA, Riethdorf S, Tucholski J, Lücke K, Wikman H, Jackson S, Brychta N, et al: Enumeration and molecular characterization of tumor cells in lung cancer patients using a novel in vivo device for capturing circulating tumor cells. Clin Cancer Res. 22:2197–2206. 2016. View Article : Google Scholar : PubMed/NCBI
16	Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P, Tomasi T, Weber E, Dworacki G, Morgenthaler NG, et al: A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol. 41:1241–1250. 2012.PubMed/NCBI
17	Mandair D, Vesely C, Ensell L, Lowe H, Spanswick V, Hartley JA, Caplin ME and Meyer T: A comparison of cellcollector with cellsearch in patients with neuroendocrine tumours. Endocr Relat Cancer. 23:L29–L32. 2016. View Article : Google Scholar : PubMed/NCBI
18	de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, et al: Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res. 13:3611–3616. 2007. View Article : Google Scholar : PubMed/NCBI
19	Cristofanilli M: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 33 (Suppl 9):S9–S14. 2006. View Article : Google Scholar : PubMed/NCBI
20	Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
21	Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, et al: Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 32:1136–1142. 2014. View Article : Google Scholar : PubMed/NCBI
22	Armstrong AJ: Epithelial-mesenchymal transition in cancer progression. Clin Adv Hematol Oncol. 9:941–943. 2011.PubMed/NCBI
23	Alix-Panabieres C and Pantel K: Circulating tumor cells: Liquid biopsy of cancer. Clin Chem. 59:110–118. 2013. View Article : Google Scholar : PubMed/NCBI
24	Lambert AW, Pattabiraman DR and Weinberg RA: Emerging biological principles of metastasis. Cell. 168:670–691. 2017. View Article : Google Scholar : PubMed/NCBI
25	Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, Nanus DM, Giannakakou PA and Kirby BJ: Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip. 10:27–29. 2010. View Article : Google Scholar : PubMed/NCBI
26	Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M and Scher HI: TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol. 60:897–904. 2011. View Article : Google Scholar : PubMed/NCBI
27	Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M, Danila DC, Flohr P, Crespo M, Figueiredo I, et al: Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer. Eur Urol. 70:985–992. 2016. View Article : Google Scholar : PubMed/NCBI
28	Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, Peng W, Sandhu SK, Olmos D, Riisnaes R, et al: Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol. 33:1348–1355. 2015. View Article : Google Scholar : PubMed/NCBI
29	Meyer CP, Pantel K, Tennstedt P, Stroelin P, Schlomm T, Heinzer H, Riethdorf S and Steuber T: Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. Urol Oncol. 34:235.e11–6. 2016. View Article : Google Scholar
30	Todenhofer T, Park ES, Duffy S, Deng X, Jin C, Abdi H, Ma H and Black PC: Microfluidic enrichment of circulating tumor cells in patients with clinically localized prostate cancer. Urol Oncol. 34:483.e9–e16. 2016. View Article : Google Scholar
31	Castle J, Morris K, Pritchard S and Kirwan CC: Challenges in enumeration of CTCs in breast cancer using techniques independent of cytokeratin expression. PLoS One. 12:e01756472017. View Article : Google Scholar : PubMed/NCBI